Skip to content

Biomarkers in the Evaluation of Chronic Lung Disease

Biomarkers in the Evaluation of Chronic Lung Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00926523
Enrollment
67
Registered
2009-06-23
Start date
2009-06-30
Completion date
2011-03-31
Last updated
2011-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease, Pulmonary Arterial Hypertension, Pulmonary Hypertension

Keywords

Pulmonary Hypertension, Pulmonary Arterial Hypertension, Interstitial Lung Disease, MIF

Brief summary

We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH.

Detailed description

We hypothesize that hypoxia-induced pulmonary vascular remodeling is mediated by macrophage migration inhibitory factor (MIF), that remodeling is in fact the reflection of a chronic inflammatory process, and that MIF may be a useful biomarker of the severity and progression of both ILD and PH. To study this hypothesis, we have two specific aims: 1. To evaluate plasma MIF concentration as a marker of severity in ILD and PH and 2. To determine the utility of breathe condensate analysis in the evaluation of ILD and PH. If we are successful in identifying MIF as a biomarker, it may identify MIF as a useful therapeutic target, as we have shown in other inflammatory disorders.

Interventions

OTHERBlood Gas

Subject will have both venous and arterial blood draws to assess for the bloods content of MIF

OTHERPulmonary Exercise Test

Subject will ride exercise bike to assess their pulmonary function level.

OTHERSpirometry

To assess subjects lung function

OTHERBreath Condensate Collector

Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.

Sponsors

Northwell Health
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subject are at least 18 years of age * Subject has confirmed Pulmonary Hypertension and Interstitial Lung Disease * Subject are able to complete study procedures, such as spirometry, and Pulmonary Exercise test.

Exclusion criteria

* Subject are pregnant * Subject is unable to perform tasks associated with study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026